Higher osimertinib introduction rate achieved by multiple repeated rebiopsy after acquired resistance to first/second generation EGFR‐TKIs

Ítems similars

• Real-world Treatment Patterns in Patients with EGFR Mutation-positive NSCLC Receiving a First-Line, First- or Second-generation EGFR Tyrosine Kinase Inhibitor in South Korea and Taiwan
  per: Jae Cheol Lee, et al.
  Publicat: (2021-05-01)
• Rebiopsy Enhances Survival with Afatinib vs. Osimertinib in EGFR Exon 19 Deletion Non-Small Cell Lung Cancer: A Multicenter Study in Taiwan
  per: Jerry Shu-Hung Kuo, et al.
  Publicat: (2025-01-01)
• Rebiopsy with Thoracoscopy under Local Anesthesia for the Detection of EGFR T790M Mutation
  per: Asako Matsuda, et al.
  Publicat: (2019-12-01)
• Clinical impact of rebiopsy among patients with epidermal growth factor receptor‐mutant lung adenocarcinoma in a real‐world clinical setting
  per: Yunha Nam, et al.
  Publicat: (2021-03-01)
• Response to Osimertinib in a Patient with Non-Small Cell Lung Cancer and Two Uncommon EGFR Mutations
  per: Christoforos Astaras, et al.
  Publicat: (2020-03-01)